<a href="https://www.fiercebiotech.com/biotech/ascidian-lilly-lock-19b-renal-disease-research-collaboration" hreflang="en">Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases</a>
Ascidian Therapeutics has partnered with Eli Lilly in a collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases, leveraging Ascidian's innovative technology and Lilly's expertise in genetic medicines. This partnership aims to address the unmet needs of inherited kidney diseases, which are often challenging for conventional gene therapies.
The collaboration between Ascidian Therapeutics and Eli Lilly, valued at up to $1.9 billion, highlights the strategic focus on RNA exon editing for genetic kidney diseases, leveraging Lilly's expertise in genetic medicines and renal disease. This partnership underscores the potential of RNA exon editing as a differentiated approach in areas where conventional gene therapy may be limited, offering significant investment and development opportunities in precision medicine. For a professional tracking healthtech and biotech innovations, this deal signals a critical advancement in tackling complex genetic disorders with novel genetic medicine technologies.